Post-Traumatic Stress Disorder Market Projected for Substantial Growth Through 2034

The expansion of the PTSD market is anticipated to be primarily fueled by rising prevalence rates, a less saturated competitive landscape, heightened public awareness campaigns, and improved disease understanding. The introduction of novel therapies, including the brexpiprazole & sertraline combination (Otsuka Pharmaceutical), BNC210 (Bionomics Limited), Psilocybin (Compass Pathways), and others, is expected to play a crucial role in reshaping the treatment landscape.

LAS VEGAS, June 26, 2025 /PRNewswire/ -- DelveInsight's Post-Traumatic Stress Disorder Market Insights report provides a comprehensive overview of current treatment practices, emerging drugs, market share by therapy, and market size projections from 2020 to 2034 across the 7MM (United States, EU4—Germany, France, Italy, Spain—the United Kingdom, and Japan).

According to DelveInsight’s analysis, the PTSD market size across the 7MM was valued at USD 1.7 billion in 2024, with the United States accounting for approximately 90% of the total market. In the same year, the 7MM reported 5.4 million diagnosed prevalent cases of PTSD, with severe cases representing nearly 37% of total prevalent cases in the US. The diagnosed population is projected to grow during 2025–2034, driven by an aging population and improved diagnostic capabilities.

The market is witnessing strong pipeline momentum, with companies such as COMPASS Pathways, Otsuka Pharmaceuticals, Bionomics Limited, Transcend Therapeutics, US WorldMeds, and Boehringer Ingelheim advancing innovative candidates including Psilocybin, REXULTI (brexpiprazole) in combination with ZOLOFT (sertraline), BNC210, Methylone (TSND-201), Lofexidine, and BI 1358894. Among these, the brexpiprazole & sertraline combination is considered a potential market-transforming therapy. 

Discover PTSD new treatment @ New Treatments for PTSD

Market dynamics are expected to shift significantly over the forecast period. Rising prevalence, expanded diagnostic recognition, and the emergence of new categories related to trauma-associated disorders are enlarging the patient pool and creating greater opportunity for therapeutic innovation. The anticipated launch of emerging therapies with improved efficacy profiles, alongside enhanced diagnosis rates, is projected to drive sustained growth across the 7MM.

However, challenges remain. PTSD is frequently accompanied by psychiatric and medical comorbidities, including substance abuse, complicating treatment outcomes and quality of life. Symptom overlap with other behavioral health disorders, stigma, limited awareness, high treatment costs, reimbursement barriers, and specialist shortages may restrain growth. Additionally, therapy failures, discontinuations, and undiagnosed cases could offset market expansion.

Current treatment approaches require a multidimensional strategy combining psychotherapy, pharmacotherapy, patient education, and social support. Psychotherapies such as Cognitive Processing Therapy (CPT), Prolonged Exposure Therapy, and Stress Inoculation Therapy remain foundational. SSRIs and SNRIs are first-line pharmacological options, with sertraline and paroxetine FDA-approved for PTSD. Adjunctive and second-line treatments—including anti-adrenergic agents, β-blockers, anticonvulsants, TCAs, MAOIs, antipsychotics, and mood stabilizers—have shown variable efficacy. 

To know more about FDA-approved drugs for PTSD, visit @ PTSD New Injection Treatment

Pipeline therapies are advancing steadily. The brexpiprazole-sertraline combination, under FDA review following an sNDA submission, is supported by late-stage data, with an advisory committee meeting held in 2025. Bionomics’ BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, reported positive Phase 2 ATTUNE trial results published in NEJM Evidence. Transcend Therapeutics presented data on TSND-201 (methylone) as a potential rapid-acting PTSD therapy at ASCP 2025. The anticipated launch of these therapies is poised to redefine standards of care and unlock new commercial opportunities. 

Discover more about post-traumatic stress disorder drugs in development @ Post-Traumatic Stress Disorder Clinical Trials

Post-traumatic stress disorder is a psychiatric condition triggered by traumatic events such as natural disasters, accidents, war, or violence. Symptoms include intrusive memories, avoidance behaviors, negative mood changes, and heightened arousal, persisting for over one month and significantly impairing daily functioning. Diagnosis relies on structured clinical assessments, as no definitive laboratory tests exist.

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

Post-Traumatic Stress Disorder (PTSD) - Epidemiology Forecast - 2034

DelveInsight’s “Post-traumatic stress disorder (PTSD)” report delivers an in-depth understanding of Post-traumatic stress disorder (PTSD), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Post-Traumatic Stress Disorder Companies developing potential therapies include - Jazz Pharmaceuticals, Otsuka Pharmaceuticals, Bionomics Limited, and others.

Post-Traumatic Stress Disorder (PTSD) - Pipeline Insight, 2026

DelveInsight’s, “Post-Traumatic Stress Disorder (PTSD) - Pipeline Insight, 2026,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Post-Traumatic Stress Disorder (PTSD) pipeline landscape. The leading Post-Traumatic Stress Disorder Companies developing potential therapies include - Jazz Pharmaceuticals, Otsuka Pharmaceuticals, Bionomics Limited, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com